Home > In process > Predicting longitudinal basal forebrain volume in the Alzheimer's disease spectrum: the role of sex and ApoE epsilon 4 genotype. > print

001     285356
005     20260225105553.0
024 7 _ |a 10.3389/fnins.2026.1730947
|2 doi
024 7 _ |a pmid:41716658
|2 pmid
024 7 _ |a pmc:PMC12913565
|2 pmc
024 7 _ |a 1662-4548
|2 ISSN
024 7 _ |a 1662-453X
|2 ISSN
037 _ _ |a DZNE-2026-00222
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Grazia, Alice
|0 P:(DE-2719)9001307
|b 0
|e First author
|u dzne
245 _ _ |a Predicting longitudinal basal forebrain volume in the Alzheimer's disease spectrum: the role of sex and ApoE epsilon 4 genotype.
260 _ _ |a Lausanne
|c 2026
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772013149_9596
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Imaging studies showed early atrophy of the cholinergic basal forebrain (BF) already at prodromal stages of sporadic Alzheimer's disease (AD). Women and carriers of the ApoE epsilon 4 (ApoE ε4) allele are more likely to develop the disease; however, the underlying mechanisms are still unclear. Here we aimed at exploring the impact of sex and ApoE ε4 genotype in the AD spectrum on longitudinal measures of the basal forebrain and hippocampus, as a comparison region.We leveraged the German multi-centered study DELCODE and analyzed 712 individuals (median age: 71.25 years, interquartile range [IQR] = 9.22) with follow-up MRI scans (median time: 2.8 years, [IQR] = 1.75). Diagnostic groups comprised cognitively normal (N = 184), subjective cognitive decline (N = 331), mild cognitive impairment (N = 128) and AD (N = 69). Regarding ApoE genotype, 5% of participants were ε4 homozygotes, while 27% were heterozygotes. Volume segmentation and linear mixed-effect models were used to calculate the effects of ApoE ε4 genotype, sex, diagnosis, age, time and their interactions in TIV-adjusted basal forebrain and hippocampal volumes.The hippocampus, but not the basal forebrain, showed significant atrophy over time (Hipp: β = -0.014, p < 0.001; BF: β = 0.040, p = 0.044). Post-TIV correction, female participants had significantly larger baseline basal forebrain (β = 0.300, p < 0.001) and hippocampal volumes (β = 0.273, p < 0.001). ApoE ε4 predicted smaller baseline volumes in both regions. After adjusting for multiple comparisons, faster longitudinal atrophy was observed only for ApoE ε4 homozygotes in the hippocampus (β = -0.037, p < 0.001), with no corresponding effect in the basal forebrain (β = 0.000, p = 0.841).Our findings did not show the anticipated longitudinal effects of sex and ApoE ε4 on longitudinal basal forebrain volume. Only hippocampal atrophy progressed significantly faster in ApoE ε4 homozygote carriers. This dissociation may reflect stage-dependent neurodegenerative processes, with early basal forebrain vulnerability followed by more rapid hippocampal decline, as well as methodological and sample-related constraints. If replicated, these findings suggest that hippocampal measures may be more sensitive longitudinal biomarkers in ApoE ε4 homozygotes, while sex- and ApoE ε4-related effects on the cholinergic system may be more prominent at earlier disease stages.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a APOE ε4
|2 Other
650 _ 7 |a basal forebrain
|2 Other
650 _ 7 |a hippocampus
|2 Other
650 _ 7 |a homozygotes
|2 Other
650 _ 7 |a sex-differences
|2 Other
700 1 _ |a Levin, Fedor
|0 P:(DE-2719)2814217
|b 1
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 2
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 3
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 4
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 5
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 6
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 7
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 8
|u dzne
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 9
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 10
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 11
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 12
|u dzne
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 13
|u dzne
700 1 _ |a Teipel, Stefan J
|0 P:(DE-2719)2000026
|b 14
|e Last author
|u dzne
773 _ _ |a 10.3389/fnins.2026.1730947
|g Vol. 20, p. 1730947
|0 PERI:(DE-600)2411902-7
|p 1730947
|t Frontiers in neuroscience
|v 20
|y 2026
|x 1662-4548
856 4 _ |u https://pub.dzne.de/record/285356/files/DZNE-2026-00222.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285356/files/DZNE-2026-00222.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001307
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2814217
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROSCI-SWITZ : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-11-09T08:11:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-11-09T08:11:26Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-11-09T08:11:26Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-11-09T08:11:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 1
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 2
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 3
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 4
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 5
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 6
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 7
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 8
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 9
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 10
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 11
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21